Genomic and Immune Profiling of Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Therapy Versus Upfront Surgery Identifies Novel Immunogenic Cell Death-Based Signatures for Predicting Clinical Outcomes

Abstract

It remains undetermined regarding the impact of neoadjuvant therapy on immunogenic cell death (ICD) and subsequent tumor microenvironment (TME) remodeling in esophageal squamous cell carcinoma (ESCC). And it is of paramount significance to identify beneficiaries from neoadjuvant therapy in treatment-naïve ESCC. In this study, 88 ESCC samples undergoing neoadjuvant therapy plus surgery (NA+S) or surgery alone (SA) were subjected to bulk-RNA sequencing. A five-gene RINscore incorporating ICD-related signature genes with TME-based hub genes was established to predict clinical outcomes and pharmacological responses, in which SLAMF7 and IL1R1 were selected out as co-expressed genes. The regulatory mechanism of the repressive co-transcription factor BATF of SLAMF7 and IL1R1 was further demonstrated. Our data demonstrated that NA+S led to high abundance in kinds of T helper cells, nature killer T cells and M1-like macrophages with increased CD8+T cells infiltration compared with SA. ICD phenotypes were further characterized in treatment-naïve ESCC to determine their differences in TME and potential benefits from NA. Our findings not only offered novel insights into the distinct TME and ICD profiles of ESCC undergoing different therapeutic modes, but also provided the RINscore, which may aid oncologists in determining individualized (neo)adjuvant immunotherapy regimen.

Keywords

esophageal squamous cell carcinoma / genomic landscape / immunogenic cell death / neoadjuvant therapy / tumor microenvironment

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[2] P. C. Enzinger and R. J. Mayer, “Esophageal Cancer,” New England Journal of Medicine 349, no. 23 (2003): 2241-2252.

[3] Y. Zhang, “Epidemiology of Esophageal Cancer,” World Journal of Gastroenterology 19, no. 34 (2013): 5598-5606.

[4] C. C. Abnet, M. Arnold, and W. Q. Wei, “Epidemiology of Esophageal Squamous Cell Carcinoma,” Gastroenterology 154, no. 2 (2018): 360-373.

[5] H. Tang, H. Wang, Y. Fang, et al., “Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Randomized Clinical Trial,” Annals of Oncology 34, no. 2 (2023): 163-172.

[6] S. Matsuda, Y. Kitagawa, R. Takemura, et al., “Real-World Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-Matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan,” Annals of Surgery 278, no. 1 (2023): e35-e42.

[7] J. M. Sun, L. Shen, M. A. Shah, et al., “Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study,” Lancet 398, no. 10302 (2021): 759-771.

[8] J. Liu, Y. Yang, Z. Liu, et al., “Multicenter, Single-Arm, Phase II Trial of Camrelizumab and Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma,” Journal for ImmunoTherapy of Cancer 10, no. 3 (2022): e004291.

[9] L. An, M. Li, and Q. Jia, “Mechanisms of Radiotherapy Resistance and Radiosensitization Strategies for Esophageal Squamous Cell Carcinoma,” Molecular Cancer 22, no. 1 (2023): 140.

[10] Z. Liu, Y. Zhang, N. Ma, et al., “Progenitor-Like Exhausted SPRY1(+) CD8(+) T Cells Potentiate Responsiveness to Neoadjuvant PD-1 Blockade in Esophageal Squamous Cell Carcinoma,” Cancer Cell 41, no. 11 (2023): 1852-1870.

[11] J. Yin, J. Yuan, Y. Li, et al., “Neoadjuvant Adebrelimab in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: A Phase 1b Trial,” Nature Medicine 29, no. 8 (2023): 2068-2078.

[12] D. Tang, R. Kang, T. V. Berghe, et al., “The Molecular Machinery of Regulated Cell Death,” Cell Research 29, no. 5 (2019): 347-364.

[13] L. Galluzzi, I. Vitale, S. A. Aaronson, et al., “Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018,” Cell Death and Differentiation 25, no. 3 (2018): 486-541.

[14] L. Galluzzi, A. Buque, O. Kepp, et al., “Immunogenic Cell Death in Cancer and Infectious Disease,” Nature Reviews Immunology 17, no. 2 (2017): 97-111.

[15] Y. Zhu, J. M. Herndon, D. K. Sojka, et al., “Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate From Embryonic Hematopoiesis and Promote Tumor Progression,” Immunity 47, no. 2 (2017): 323-338.

[16] X. Wang, S. Wu, F. Liu, et al., “An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma,” Frontiers in Immunology 12 (2021): 781466.

[17] Z. Liu, L. Sun, X. Peng, et al., “An Immunogenic Cell Death-Related Signature Predicts Prognosis and Immunotherapy Response in Stomach Adenocarcinoma,” Apoptosis 28, no. 11 (2023): 1564-1583.

[18] T. N. Schumacher and R. D. Schreiber, “Neoantigens in Cancer Immunotherapy,” Science 348, no. 6230 (2015): 69-74.

[19] J. Shapiro, J. van Lanschot, M. Hulshof, et al., “Neoadjuvant Chemoradiotherapy Plus Surgery Versus Surgery Alone for Oesophageal or Junctional Cancer (CROSS): Long-Term Results of a Randomised Controlled Trial,” Lancet Oncology 16, no. 9 (2015): 1090-1098.

[20] P. Meier, A. J. Legrand, D. Adam, et al., “Immunogenic Cell Death in Cancer: Targeting Necroptosis to Induce Antitumour Immunity,” Nature Reviews Cancer 24, no. 5 (2024): 299-315.

[21] X. Zhang, L. Peng, Y. Luo, et al., “Dissecting Esophageal Squamous-Cell Carcinoma Ecosystem by Single-Cell Transcriptomic Analysis,” Nature Communications 12, no. 1 (2021): 5291.

[22] J. Yao, Q. Cui, W. Fan, et al., “Single-Cell Transcriptomic Analysis in a Mouse Model Deciphers Cell Transition States in the Multistep Development of Esophageal Cancer,” Nature Communications 11, no. 1 (2020): 3715.

[23] H. Q. Dinh, F. Pan, G. Wang, et al., “Integrated Single-Cell Transcriptome Analysis Reveals Heterogeneity of Esophageal Squamous Cell Carcinoma Microenvironment,” Nature Communications 12, no. 1 (2021): 7335.

[24] D. Dangaj, M. Bruand, A. J. Grimm, et al., “Cooperation Between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors,” Cancer Cell 35, no. 6 (2019): 885-900.

[25] Z. Chen, Y. Huang, Z. Hu, et al., “Dissecting the Single-Cell Transcriptome Network in Patients With Esophageal Squamous Cell Carcinoma Receiving Operative Paclitaxel Plus Platinum Chemotherapy,” Oncogensis 10, no. 10 (2021): 71.

[26] Y. Z. Jiang, D. Ma, C. Suo, et al., “Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies,” Cancer Cell 35, no. 3 (2019): 428-440.

[27] P. S. Hegde and D. S. Chen, “Top 10 Challenges in Cancer Immunotherapy,” Immunity 52, no. 1 (2020): 17-35.

[28] D. I. Gabrilovich and S. Nagaraj, “Myeloid-Derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology 9, no. 3 (2009): 162-174.

[29] M. F. Sanmamed and L. Chen, “A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization,” Cell 175, no. 2 (2018): 313-326.

[30] K. Cao, J. Zhu, M. Lu, et al., “Analysis of Multiple Programmed Cell Death-Related Prognostic Genes and Functional Validations of Necroptosis-Associated Genes in Oesophageal Squamous Cell Carcinoma,” Ebiomedicine 99 (2024): 104920.

[31] C.-M. ME, Z. Dong, X. Shi, et al., “Influence of CRACC, a SLAM Family Receptor Coupled to the Adaptor EAT-2, on Natural Killer Cell Function,” Nature Immunology 10, no. 3 (2009): 297-305.

[32] L. A. Perez-Quintero, R. Roncagalli, H. Guo, et al., “EAT-2, a SAP-Like Adaptor, Controls NK Cell Activation Through Phospholipase Cgamma, Ca++, and Erk, Leading to Granule Polarization,” Journal of Experimental Medicine 211, no. 4 (2014): 727-742.

[33] P. O'Connell, S. Hyslop, M. K. Blake, et al., “SLAMF7 Signaling Reprograms T Cells Toward Exhaustion in the Tumor Microenvironment,” Journal of Immunology 206, no. 1 (2021): 193-205.

[34] P. O'Connell, M. K. Blake, Y. Pepelyayeva, et al., “Adenoviral Delivery of an Immunomodulatory Protein to the Tumor Microenvironment Controls Tumor Growth,” Molecular Therapy-Oncolytics 24 (2022): 180-193.

[35] Y. Zhang, H. Chen, H. Mo, et al., “Single-Cell Analyses Reveal Key Immune Cell Subsets Associated With Response to PD-L1 Blockade in Triple-Negative Breast Cancer,” Cancer Cell 39, no. 12 (2021): 1578-1593.

[36] H. Fujita, T. Kakegawa, H. Yamana, et al., “Mortality and Morbidity Rates, Postoperative Course, Quality of Life, and Prognosis After Extended Radical Lymphadenectomy for Esophageal Cancer. Comparison of Three-Field Lymphadenectomy With Two-Field Lymphadenectomy,” Annals of Surgery 222, no. 5 (1995): 654-662.

[37] T. W. Rice, H. Ishwaran, M. K. Ferguson, et al., “Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer,” Journal of Thoracic Oncology 12, no. 1 (2017): 36-42.

[38] D. Kim, B. Langmead, and S. L. Salzberg, “HISAT: A Fast Spliced Aligner With Low Memory Requirements,” Nature Methods 12, no. 4 (2015): 357-360.

[39] M. E. Ritchie, B. Phipson, D. Wu, et al., “Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies,” Nucleic Acids Research 43, no. 7 (2015): e47.

[40] D. Aran, Z. Hu, and A. J. Butte, “xCell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape,” Genome Biology 18, no. 1 (2017): 220.

[41] D. Yang, Y. Zhou, Y. Zhang, et al., “Comprehensive Analysis of scRNA-Seq and Bulk RNA-Seq Data Reveals Dynamic Changes in Tumor-Associated Neutrophils in the Tumor Microenvironment of Hepatocellular Carcinoma and Leads to the Establishment of a Neutrophil-Related Prognostic Model,” Cancer Immunology, Immunotherapy 72, no. 12 (2023): 4323-4335.

[42] V. Thorsson, D. L. Gibbs, S. D. Brown, et al., “The Immune Landscape of Cancer,” Immunity 48, no. 4 (2018): 812-830.

[43] A. D. Garg, D. De Ruysscher, and P. Agostinis, “Immunological Metagene Signatures Derived From Immunogenic Cancer Cell Death Associate With Improved Survival of Patients With Lung, Breast or Ovarian Malignancies: A Large-Scale Meta-Analysis,” Oncoimmunlogy 5, no. 2 (2016): e1069938.

[44] L. Galluzzi, I. Vitale, S. Warren, et al., “Consensus Guidelines for the Definition, Detection and Interpretation of Immunogenic Cell Death,” Journal for ImmunoTherapy of Cancer 8, no. 1 (2020): e000337.

[45] M. D. Wilkerson and D. N. Hayes, “ConsensusClusterPlus: A Class Discovery Tool With Confidence Assessments and Item Tracking,” Bioinformatics 26, no. 12 (2010): 1572-1573.

[46] A. Liberzon, A. Subramanian, R. Pinchback, et al., “Molecular Signatures Database (MSigDB) 3.0,” Bioinformatics 27, no. 12 (2011): 1739-1740.

[47] A. Subramanian, P. Tamayo, V. K. Mootha, et al., “Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles,” Proceedings of the National Academy of Sciences 102, no. 43 (2005): 15545-15550.

[48] I. S. Lossos, D. K. Czerwinski, A. A. Alizadeh, et al., “Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes,” New England Journal of Medicine 350, no. 18 (2004): 1828-1837.

[49] G. D'Arrigo, D. Leonardis, E. S. Abd, et al., “Methods to Analyse Time-to-Event Data: The Kaplan-Meier Survival Curve,” Oxidative Medicine and Cellular Longevity 2021 (2021): 2290120.

[50] F. Zhang, Y. Sang, D. Chen, et al., “M2 Macrophage-Derived Exosomal Long Non-Coding RNA AGAP2-AS1 Enhances Radiotherapy Immunity in Lung Cancer by Reducing microRNA-296 and Elevating NOTCH2,” Cell Death & Disease 12, no. 5 (2021): 467.

[51] M. Shen, Z. Xu, W. Xu, et al., “Inhibition of ATM Reverses EMT and Decreases Metastatic Potential of Cisplatin-Resistant Lung Cancer Cells Through JAK/STAT3/PD-L1 Pathway,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 149.

[52] W. Shen, Z. Song, X. Zhong, et al., “Sangerbox: A Comprehensive, Interaction-Friendly Clinical Bioinformatics Analysis Platform,” Imeta 1, no. 3 (2022): e36.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.